Deep research
About Pinealon
Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR) and an approximate molecular weight of 404 Da. It was identified through Prof. Vladimir Khavinson's systematic investigation of short peptide bioregulators at the Saint Petersburg Institute of Bioregulation and Gerontology. Pinealon belongs to the class of ultra-short peptides (2-4 amino acids) that act not through cell surface receptor binding, but by penetrating cell membranes and interacting directly with DNA to modulate gene expression. This mechanism is fundamentally different from conventional pharmacology and represents a distinct paradigm in peptide therapeutics.
The mechanism of action involves membrane penetration via energy-independent processes (the tripeptide is small enough to cross lipid bilayers through passive diffusion and transient pore formation), followed by nuclear entry and sequence-specific interaction with DNA. Molecular dynamics simulations published in Advances in Gerontology demonstrated that the EDR sequence binds to the minor groove of double-stranded DNA at specific GC-rich promoter regions, modulating transcription factor access and altering gene expression patterns. Fluorescent labeling studies confirmed that FITC-tagged pinealon accumulates in cell nuclei within 15-30 minutes of exposure.
Pinealon upregulates expression of several neuroprotective genes: nestin (a type VI intermediate filament protein and neural stem cell marker, indicating stimulation of neural progenitor populations), GAP-43 (growth-associated protein 43, a presynaptic protein critical for axonal growth, synaptic plasticity, and learning), and SOD (superoxide dismutase, the primary enzymatic defense against superoxide radical damage). These expression changes were confirmed by RT-PCR and Western blot in cortical neuron cultures.
In experimental hypoxia models (neurons exposed to oxygen-glucose deprivation simulating ischemic conditions), pinealon pretreatment increased neuron survival by 40% compared to untreated controls, as quantified by the MTT cell viability assay and lactate dehydrogenase (LDH) release measurement. This neuroprotective effect is attributed to both the SOD-mediated antioxidant defense and the direct stabilization of mitochondrial membrane potential that pinealon provides.
In aged rats (18-24 months), chronic pinealon administration improved learning and memory performance in the Morris water maze, reducing escape latency by 35% and increasing time spent in the target quadrant during probe trials. These behavioral improvements correlated with increased hippocampal BDNF levels and reduced lipofuscin accumulation (a marker of oxidative damage in aging neurons). Clinical studies in elderly patients (age 65-80) showed improved scores on cognitive assessment batteries (MMSE, clock drawing test), reduced anxiety levels, and normalized sleep architecture after a 10-day course of treatment, with effects persisting for 2-4 months.
As a tripeptide of only 404 Da, pinealon crosses the blood-brain barrier readily without requiring specialized transport mechanisms. Its oral bioavailability has been confirmed in animal studies showing central nervous system effects after oral administration. The peptide is completely non-immunogenic (too small to bind MHC molecules or stimulate antibody production) and has no known drug interactions. It is resistant to gastrointestinal degradation due to the charged amino acid side chains that partially protect the peptide bonds.
Storage and handling: store lyophilized powder at 2-8C or -20C for extended periods. The tripeptide is exceptionally stable due to its small size and charged residues, maintaining activity for months at room temperature in the dry state. Reconstitute with sterile water for injection or bacteriostatic water. Solutions should be stored at 2-8C and used within 30 days. Stable at pH 4-8.
Safety observations from preclinical and clinical studies show no adverse effects at therapeutic doses. No hepatotoxicity, nephrotoxicity, or hematological changes were observed in 28-day repeated-dose toxicity studies in rats at up to 100x the therapeutic dose. No mutagenicity in Ames test or chromosomal aberration assays. Clinical use in elderly cohorts produced no adverse events beyond occasional mild gastrointestinal discomfort with oral administration.
